Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Intangibles (2016 - 2025)

Ani Pharmaceuticals' Intangibles history spans 12 years, with the latest figure at $15.8 million for Q2 2025.

  • For Q2 2025, Intangibles changed N/A year-over-year to $15.8 million; the TTM value through Jun 2025 reached $15.8 million, changed N/A, while the annual FY2024 figure was $541.8 million, N/A changed from the prior year.
  • Intangibles for Q2 2025 was $15.8 million at Ani Pharmaceuticals, down from $541.8 million in the prior quarter.
  • Across five years, Intangibles topped out at $541.8 million in Q4 2024 and bottomed at $4.3 million in Q2 2023.
  • The 5-year median for Intangibles is $257.9 million (2022), against an average of $262.3 million.
  • The largest annual shift saw Intangibles soared 165.5% in 2021 before it tumbled 49.72% in 2022.
  • A 5-year view of Intangibles shows it stood at $500.5 million in 2021, then crashed by 49.72% to $251.6 million in 2022, then plummeted by 98.29% to $4.3 million in 2023, then soared by 12500.79% to $541.8 million in 2024, then crashed by 97.08% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Intangibles are $15.8 million (Q2 2025), $541.8 million (Q4 2024), and $4.3 million (Q2 2023).